Histone Methylation and STAT-3 Differentially Regulate Interleukin-6-Induced Matrix Metalloproteinase Gene Activation in Rheumatoid Arthritis Synovial Fibroblasts

Arthritis and Rheumatology

Volumn 68, Issue 5, 2016, Pages 1111-1123

  Araki, Yasuto ^a   Tsuzuki Wada, Takuma ^a   Aizaki, Yoshimi ^a   Sato, Kojiro ^a   Yokota, Kazuhiro ^a   Fujimoto, Kenta ^a   Kim, Yoon Taek ^a   Oda, Hiromi ^a   Kurokawa, Riki ^a   Mimura, Toshihide ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE B; HISTONE; HISTONE H3; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LYSINE; MATRIX METALLOPROTEINASE; MESSENGER RNA; STAT3 PROTEIN; STROMELYSIN; IL6 PROTEIN, HUMAN; MMP1 PROTEIN, HUMAN; MMP13 PROTEIN, HUMAN; MMP3 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; SMALL INTERFERING RNA; STAT3 PROTEIN, HUMAN;

ARTICLE; CELL STIMULATION; CHROMATIN STRUCTURE; CONTROLLED STUDY; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROBLAST; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; CASE CONTROL STUDY; CHROMATIN IMMUNOPRECIPITATION; CYTOLOGY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HISTONE CODE; IMMUNOLOGY; KNEE OSTEOARTHRITIS; METABOLISM; METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVIUM; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHROMATIN IMMUNOPRECIPITATION; FIBROBLASTS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HISTONE CODE; HISTONES; HUMANS; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; METHYLATION; OSTEOARTHRITIS, KNEE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; SYNOVIAL MEMBRANE; TRANSCRIPTIONAL ACTIVATION;

EID: 84964626192     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39563     Document Type: Article

References (50)

1. Firestein GS., Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
2. Bartok B, Firestein GS., Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 233-55.
3. Frisenda S, Perricone C, Valesini G., Cartilage as a target of autoimmunity: a thin layer. Autoimmun Rev 2013; 12: 591-8.
4. Rengel Y, Ospelt C, Gay S., Proteinases in the joint: clinical relevance of proteinases in joint destruction. Arthritis Res Ther 2007; 9: 221.
5. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al., Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000; 43: 852-8.
6. Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, et al., Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 83-8.
7. Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Kamatani N, et al., Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol 2007; 17: 403-8.
8. Litinsky I, Paran D, Levartovsky D, Wigler I, Kaufman I, Yaron I, et al., The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine 2006; 33: 106-10.
9. Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, et al., Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 484-9.
10. Martel-Pelletier J, Welsch DJ, Pelletier JP., Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 2001; 15: 805-29.
11. Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, et al., Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988; 18: 1797-801.
12. Costenbader KH, Gay S, Alarcon-Riquelme ME, Iaccarino L, Doria A., Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev 2012; 11: 604-9.
13. Aho K, Koskenvuo M, Tuominen J, Kaprio J., Occurrence of rheumatoid arthritis in a nationwide series of twins. J Rheumatol 1986; 13: 899-902.
14. Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, et al., Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol 1993; 32: 903-7.
15. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, Aho K, et al., Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000; 43: 30-7.
16. Gregersen PK, Silver J, Winchester RJ., The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.
17. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al., Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014; 506: 376-81.
18. Klareskog L, Padyukov L, Alfredsson L., Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol 2007; 19: 49-54.
19. Munz C, Lunemann JD, Getts MT, Miller SD., Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 2009; 9: 246-58.
20. Wegner N, Wait R, Sroka A, Eick S, Nguyen KA, Lundberg K, et al., Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010; 62: 2662-72.
21. Stolt P, Kallberg H, Lundberg I, Sjogren B, Klareskog L, Alfredsson L, et al., Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis 2005; 64: 582-6.
22. Klein K, Ospelt C, Gay S., Epigenetic contributions in the development of rheumatoid arthritis. Arthritis Res Ther 2012; 14: 227.
23. Weng NP, Araki Y, Subedi K., The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation. Nat Rev Immunol 2012; 12: 306-15.
24. Takada S, Asahara H., Current strategies for microRNA research. Mod Rheumatol 2012; 22: 645-53.
25. Berger SL., The complex language of chromatin regulation during transcription. Nature 2007; 447: 407-12.
26. Kouzarides T., Chromatin modifications and their function. Cell 2007; 128: 693-705.
27. Li B, Carey M, Workman JL., The role of chromatin during transcription. Cell 2007; 128: 707-19.
28. Wada TT, Araki Y, Sato K, Aizaki Y, Yokota K, Kim YT, et al., Aberrant histone acetylation contributes to elevated interleukin-6 production in rheumatoid arthritis synovial fibroblasts. Biochem Biophys Res Commun 2014; 444: 682-6.
29. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
30. Araki Y, Fann M, Wersto R, Weng NP., Histone acetylation facilitates rapid and robust memory CD8 T cell response through differential expression of effector molecules (eomesodermin and its targets: perforin and granzyme B). J Immunol 2008; 180: 8102-8.
31. Araki Y, Wang Z, Zang C, Wood WH III, Schones D, Cui K, et al., Genome-wide analysis of histone methylation reveals chromatin state-based regulation of gene transcription and function of memory CD8+ T cells. Immunity 2009; 30: 912-25.
32. Zaret K., Micrococcal nuclease analysis of chromatin structure. Curr Protoc Mol Biol 2005; 21: 21.1.
33. Shilatifard A., The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem 2012; 81: 65-95.
34. Trievel RC, Shilatifard A., WDR5, a complexed protein. Nat Struct Mol Biol 2009; 16: 678-80.
35. Ang YS, Tsai SY, Lee DF, Monk J, Su J, Ratnakumar K, et al., Wdr5 mediates self-renewal and reprogramming via the embryonic stem cell core transcriptional network. Cell 2011; 145: 183-97.
36. Vaes G, Eeckhout Y, Lenaers-Claeys G, Francois-Gillet C, Druetz JE., The simultaneous release by bone explants in culture and the parallel activation of procollagenase and of a latent neutral proteinase that degrades cartilage proteoglycans and denatured collagen. Biochem J 1978; 172: 261-74.
37. Okada Y, Nagase H, Harris ED Jr., A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components: purification and characterization. J Biol Chem 1986; 261: 14245-55.
38. Vartio T, Baumann M., Human gelatinase/type IV procollagenase is a regular plasma component. FEBS Lett 1989; 255: 285-9.
39. Freije JM, Diez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, et al., Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994; 269: 16766-73.
40. Burrage PS, Mix KS, Brinckerhoff CE., Matrix metalloproteinases: role in arthritis. Front Biosci 2006; 11: 529-43.
41. Klein BJ, Piao L, Xi Y, Rincon-Arano H, Rothbart SB, Peng D, et al., The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers. Cell Rep 2014; 6: 325-35.
42. Wang F, Sengupta TK, Zhong Z, Ivashkiv LB., Regulation of the balance of cytokine production and the signal transducer and activator of transcription (STAT) transcription factor activity by cytokines and inflammatory synovial fluids. J Exp Med 1995; 182: 1825-31.
43. Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M., DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60: 3613-22.
44. Takami N, Osawa K, Miura Y, Komai K, Taniguchi M, Shiraishi M, et al., Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells. Arthritis Rheum 2006; 54: 779-87.
45. Nakano K, Whitaker JW, Boyle DL, Wang W, Firestein GS., DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 110-7.
46. Whitaker JW, Shoemaker R, Boyle DL, Hillman J, Anderson D, Wang W, et al., An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotype. Genome Med 2013; 5: 40.
47. Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, et al., Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008; 58: 1001-9.
48. Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, Kolling C, et al., Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 2011; 63: 373-81.
49. Trenkmann M, Brock M, Gay RE, Kolling C, Speich R, Michel BA, et al., Expression and function of EZH2 in synovial fibroblasts: epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis. Ann Rheum Dis 2011; 70: 1482-8.
50. Scheinecker C, Redlich K, Smolen JS., Cytokines as therapeutic targets: advances and limitations. Immunity 2008; 28: 440-4.